Also categorized in BoardMoves:
What Lies Ahead For Chesapeake As McClendon Exits?
x hide permanently

Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors


Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies, announced today the appointment of Elliott Sigal, M.D., Ph.D., to the company’s Board of Directors...

Mentions: Elliott Affinia Therapeutics Elliott Sigal